TY - JOUR
T1 - Klotho as a potential biomarker and therapy for acute kidney injury
AU - Hu, Ming C
AU - Moe, Orson W
N1 - Funding Information:
The authors were supported by the NIH (R01-DK091392 and R01-DK092461), the George M. O’Brien Kidney Research Center/University of Texas Southwestern Medical Center (P30-DK-07938), American Heart Association (0865235F), the Simmons Family Foundation and a Seed Grant from the Charles and Jane Pak Center for Mineral Metabolism and Clinical Research, University of Texas Southwestern Medical Center. The authors would like to thank M. Kuro-o for long-term valuable collaboration, and M. Shi for expert assistance with some key experiments performed in the authors’ laboratories cited in this article.
PY - 2012/7
Y1 - 2012/7
N2 - Klotho is a single-pass transmembrane protein that is highly expressed in the kidney and is known to act as a coreceptor for fibroblast growth factor 23. The extracellular domain can be produced independently or shed from membrane-bound Klotho and functions as an endocrine substance with multiple functions including antioxidation, modulation of ion transport, suppression of fibrosis, and preservation of stem cells. Emerging evidence has revealed that Klotho deficiency is an early event in acute kidney injury (AKI), and a pathogenic factor that exacerbates acute kidney damage and contributes to long-term consequences. Restoration by exogenous supplementation or stimulation of endogenous Klotho might prevent and ameliorate injury, promote recovery, and suppress fibrosis to mitigate development of chronic kidney disease. Although data are still emerging, in this Perspectives article we discuss why this renal-derived protein is a highly promising candidate as both an early biomarker and therapeutic agent for AKI.
AB - Klotho is a single-pass transmembrane protein that is highly expressed in the kidney and is known to act as a coreceptor for fibroblast growth factor 23. The extracellular domain can be produced independently or shed from membrane-bound Klotho and functions as an endocrine substance with multiple functions including antioxidation, modulation of ion transport, suppression of fibrosis, and preservation of stem cells. Emerging evidence has revealed that Klotho deficiency is an early event in acute kidney injury (AKI), and a pathogenic factor that exacerbates acute kidney damage and contributes to long-term consequences. Restoration by exogenous supplementation or stimulation of endogenous Klotho might prevent and ameliorate injury, promote recovery, and suppress fibrosis to mitigate development of chronic kidney disease. Although data are still emerging, in this Perspectives article we discuss why this renal-derived protein is a highly promising candidate as both an early biomarker and therapeutic agent for AKI.
UR - http://www.scopus.com/inward/record.url?scp=84862840249&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84862840249&partnerID=8YFLogxK
U2 - 10.1038/nrneph.2012.92
DO - 10.1038/nrneph.2012.92
M3 - Review article
C2 - 22664739
AN - SCOPUS:84862840249
SN - 1759-5061
VL - 8
SP - 423
EP - 429
JO - Nature Reviews Nephrology
JF - Nature Reviews Nephrology
IS - 7
ER -